JAMA Neurology · 2024 · 14 citations · 12 references
MedicineNeurosurgerySurgeryCerebrovascular SurgeryMicrosurgeryVascular SurgeryAneurysm SurgeryCerebral Vasospasm ManagementCerebrovascular DiseaseSubarachnoid HemorrhageSubarachnoid Hemorrhage ManagementAneurysm Rupture PreventionAneurysmal Subarachnoid Hemorrhage VasospasmCerebral Aneurysm RuptureCerebral VasculatureCerebral Vasospasm PreventionElective Aneurysm RepairIntraoperative Digital Subtraction AngiographyMicrosurgical Aneurysm Surgery
Importance: Cerebral vasospasm largely contributes to a devastating outcome after aneurysmal subarachnoid hemorrhage (aSAH), with limited therapeutic options. Objective: To investigate the safety and efficacy of localized nicardipine release implants positioned around the basal cerebral vasculature at risk for developing proximal vasospasm after aSAH. Design, Setting, and Participants: This single-masked randomized clinical trial with a 52-week follow-up was performed between April 5, 2020, and January 23, 2023, at 6 academic neurovascular centers in Germany and Austria. Consecutive patients with World Federation of Neurological Surgeons grade 3 or 4 aSAH due to a ruptured anterior circulation aneurysm requiring microsurgical aneurysm repair participated. Intervention: During aneurysm repair, patients were randomized 1:1 to intraoperatively receive 10 implants at 4 mg of nicardipine each plus standard of care (implant group) or aneurysm repair alone plus standard of care (control group). Main Outcome and Measures: The primary end point was the incidence of moderate to severe cerebral angiographic vasospasm (aVS) between days 7 and 9 after aneurysm rupture as determined by digital subtraction angiography. Results: Of 41 patients, 20 were randomized to the control group (mean [SD] age, 54.9 [9.1] years; 17 female [85%]) and 21 to the implant group (mean [SD] age, 53.6 [11.9] years; 14 female [67%]). A total of 39 patients were included in the primary efficacy analysis. In the control group, 11 of 19 patients (58%) developed moderate or severe aVS compared with 4 of 20 patients (20%) in the implant group (P = .02). This outcome was paralleled by a lower clinical need for vasospasm rescue therapy in the implant group (2 of 20 patients [10%]) compared with the control group (11 of 19 patients [58%]; P = .002). Between days 13 and 15 after aneurysm rupture, new cerebral infarcts were noted in 6 of 19 patients (32%) in the control group and in 2 of 20 patients (10%) in the implant group (P = .13). At 52 weeks, favorable outcomes were noted in 12 of 18 patients (67%) in the control group and 16 of 19 patients (84%) in the implant group (P = .27). The adverse event rate did not differ between groups. Conclusions and Relevance: These findings show that placing nicardipine release implants during microsurgical aneurysm repair can provide safe and effective prevention of moderate to severe aVS after aSAH. A phase 3 clinical trial to investigate the effect of nicardipine implants on clinical outcome may be warranted. Trial Registration: ClinicalTrials.gov Identifier: NCT04269408.
12
World Medical Association Declaration of Helsinki
JAMA · 2013 · 29.4K citations
Andrew Molyneux, Richard Kerr, Jacqueline Birks et al. · The Lancet Neurology · 2009 · 906 citations · Full text
Medicine, Neurosurgery, Surgery +17
PREDICTION OF SYMPTOMATIC VASOSPASMAFTER SUBARACHNOID HEMORRHAGE
Jennifer Frontera, Jan Claassen, J. Michael Schmidt et al. · Neurosurgery · 2006 · 319 citations
Angiographic Vasospasm Is Strongly Correlated With Cerebral Infarction After Subarachnoid Hemorrhage
R. Webster Crowley, Ricky Medel, Aaron S. Dumont et al. · Stroke · 2011 · 271 citations
Medicine, Neurology, Neurosurgery +16